Literature DB >> 10408873

Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands.

K Flavell1, C Constandinou, D Lowe, K Scott, C Newey, D Evans, A Dutton, S Simmons, R Smith, J Crocker, L S Young, P Murray.   

Abstract

We have used Townsend scores from postcode data to compare levels of material deprivation and Epstein-Barr virus (EBV)-positivity for 223 patients diagnosed with Hodgkin's disease (HD) in the period 1981-1997. The presence of EBV in HD tumours was determined using in situ hybridization to target the abundantly expressed EBV early RNAs. EBV was detected in the malignant Hodgkin and Reed-Sternberg cells in 47/223 HD cases (21%). There was found to be a tendency for higher Townsend scores (indicative of higher levels of material deprivation) in EBV-positive HD patients, but this association was not statistically significant. When various subgroups of patients from the study were examined separately the indication of higher Townsend scores in EBV-positive patients was found to be more marked for patients with mixed cellularity disease (P = 0.09) and for females (P = 0.03). The results of this study suggest that differences in the level of material deprivation are important in determining the likelihood of EBV-positive HD in the UK, particularly for certain subgroups of patients. It is not known what specific socioeconomic factors are responsible for these differences, although alterations in the timing or rate of primary EBV infection, or decline in the level of EBV-specific immunity, may be important.

Entities:  

Mesh:

Year:  1999        PMID: 10408873      PMCID: PMC2362323          DOI: 10.1038/sj.bjc.6690398

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease.

Authors:  H Herbst; E Steinbrecher; G Niedobitek; L S Young; L Brooks; N Müller-Lantzsch; H Stein
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

Review 2.  The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma.

Authors:  H Stein; H Herbst; I Anagnostopoulos; G Niedobitek; F Dallenbach; H C Kratzsch
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

3.  Which deprivation? A comparison of selected deprivation indexes.

Authors:  R Morris; V Carstairs
Journal:  J Public Health Med       Date:  1991-11

4.  Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis.

Authors:  A A Armstrong; F E Alexander; R Cartwright; B Angus; A S Krajewski; D H Wright; I Brown; F Lee; E Kane; R F Jarrett
Journal:  Leukemia       Date:  1998-08       Impact factor: 11.528

5.  Multiple deprivation and health state.

Authors:  V Carstairs
Journal:  Community Med       Date:  1981-02

6.  Small area analysis and health service research.

Authors:  V Carstairs
Journal:  Community Med       Date:  1981-05

7.  Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization.

Authors:  I Anagnostopoulos; H Herbst; G Niedobitek; H Stein
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

8.  The association between Epstein-Barr virus and Chinese Hodgkin's disease.

Authors:  X G Zhou; S J Hamilton-Dutoit; Q H Yan; G Pallesen
Journal:  Int J Cancer       Date:  1993-09-30       Impact factor: 7.396

9.  BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders.

Authors:  P G Murray; L J Swinnen; C M Constandinou; J M Pyle; T J Carr; J M Hardwick; R F Ambinder
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

10.  The distinction of Hodgkin's disease from anaplastic large cell lymphoma.

Authors:  G Frizzera
Journal:  Semin Diagn Pathol       Date:  1992-11       Impact factor: 3.464

View more
  8 in total

1.  Detection of Epstein-Barr virus in archival Hodgkin's disease specimens.

Authors:  K J Flavell; J A Linford; J R Flavell; P G Murray; L S Young; K Scott
Journal:  Mol Pathol       Date:  2000-06

Review 2.  Hodgkin's disease and the Epstein-Barr virus.

Authors:  K J Flavell; P G Murray
Journal:  Mol Pathol       Date:  2000-10

Review 3.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

Review 4.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

5.  Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.

Authors:  Sally L Glaser; Margaret L Gulley; Christina A Clarke; Theresa H Keegan; Ellen T Chang; Sarah J Shema; Fiona E Craig; Joseph A Digiuseppe; Ronald F Dorfman; Risa B Mann; Hoda Anton-Culver; Richard F Ambinder
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

6.  Maternal and perinatal factors associated with hospitalised infectious mononucleosis in children, adolescents and young adults: record linkage study.

Authors:  Imran Mahmud; Omar A Abdel-Mannan; Clare J Wotton; Michael J Goldacre
Journal:  BMC Infect Dis       Date:  2011-02-28       Impact factor: 3.090

7.  South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease.

Authors:  K J Flavell; J P Biddulph; J E Powell; S E Parkes; D Redfern; M Weinreb; P Nelson; J R Mann; L S Young; P G Murray
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

8.  Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters.

Authors:  Atif Ali Hashmi; Zubaida Fida Hussain; Kashif Ali Hashmi; Muhammad Irfan Zafar; Muhammad Muzzammil Edhi; Naveen Faridi; Mehmood Khan
Journal:  World J Surg Oncol       Date:  2017-04-20       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.